Zenas BioPharma Touts Phase 3 Win, But Stock Crashes - Zenas BioPharma (NASDAQ:ZBIO)

Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compete With Amgen?

Zenas Biopharma’s obexelimab achieved a statistically significant and clinically meaningful reduction in signs and symptoms of immunoglobulin G4-related disease, but not to the extent shown by Amgen’s Uplizna in its pivotal study. Still, Zenas points to features of its drug that could make it competitive as a maintenance therapy for the rare autoimmune disorder. The post Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compet…

Zenas shares crash after top drug misses expectations in immune disease study

While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear to match the effectiveness of a recently approved Amgen drug.

Zenas BioPharma Touts Phase 3 Win, But Stock Crashes - Zenas BioPharma (NASDAQ:ZBIO)

Zenas BioPharma shares fall after Phase 3 obexelimab data in IgG4-RD showed a 56% flare risk reduction, as investors weigh competition from Amgen's FDA-approved Uplizna.

Zenas’ stock drops 51% despite lead asset’s Phase III rare disease win

While obexelimab failed to best Uplizna in terms of efficacy, Zenas will still file for the drug’s approval in IgG4-RD.The post Zenas’ stock drops 51% despite lead asset’s Phase III rare disease win appeared first on Clinical Trials Arena.

Zenas BioPharma Shares Decline After Obexelimab Trial Results Show Lower Effectiveness Compared to Amgen Treatment

Shares of Zenas BioPharma experienced a significant dro […] The post Zenas BioPharma Shares Decline After Obexelimab Trial Results Show Lower Effectiveness Compared to Amgen Treatment first appeared on GeneOnline News. The post Zenas BioPharma Shares Decline After Obexelimab Trial Results Show Lower Effectiveness Compared to Amgen Treatment appeared first on GeneOnline News.

Zenas BioPharma’s Phase 3 autoimmune disease readout falls short, sending shares plummeting

Zenas BioPharma said its experimental antibody succeeded in a pivotal study for IgG4-related disease, an autoimmune condition, and that it plans to seek FDA approval. But the topline findings compare poorly to an on-the-market rival ...